Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

HANGZHOU, China, Jan. 19, 2018 /PRNewswire/ -- Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global...

Leave a comment

Your email address will not be published.